StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.57−0.13 (-3.51%)

Close on Nov 18, 2026Market cap $99.44MP/E –Yield –

Unicycive Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Unicycive Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$27.84M. For fiscal 2025 it was -$31.32M. The highest annual figure on record is -$1.46M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$31.32M–
FY2024Dec 31, 2024-$28.58M–
FY2023Dec 31, 2023-$18.28M–
FY2022Dec 31, 2022-$15.65M–
FY2021Dec 31, 2021-$5.77M–
FY2020Dec 31, 2020-$1.46M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.60M–
Q1 FY2026Mar 31, 2026-$6.24M–
Q4 FY2025Dec 31, 2025-$8.03M–
Q3 FY2025Sep 30, 2025-$5.96M–
Q2 FY2025Jun 30, 2025-$8.42M–
Q1 FY2025Mar 31, 2025-$8.90M–
Q4 FY2024Dec 31, 2024-$6.55M–
Q3 FY2024Sep 30, 2024-$9.25M–
Q2 FY2024Jun 30, 2024-$6.32M–
Q1 FY2024Mar 31, 2024-$6.46M–
Q4 FY2023Dec 31, 2023-$4.44M–
Q3 FY2023Sep 30, 2023-$4.42M–
Q2 FY2023Jun 30, 2023-$5.50M–
Q1 FY2023Mar 31, 2023-$3.92M–
Q4 FY2022Dec 31, 2022-$6.08M–
Q3 FY2022Sep 30, 2022-$3.56M–
Q2 FY2022Jun 30, 2022-$3.05M–
Q1 FY2022Mar 31, 2022-$2.96M–
Q4 FY2021Dec 31, 2021-$1.40M–
Q3 FY2021Sep 30, 2021-$3.47M–
Q2 FY2021Jun 30, 2021-$217.00K–
Q1 FY2021Mar 31, 2021-$673.00K–
Q4 FY2020Dec 31, 2020-$538.00K–
Q3 FY2020Sep 30, 2020-$706.00K–

More Unicycive Therapeutics figures

See a number that looks wrong?